Health Economics›Renal cell carcinoma›Metastatic disease, first-line

Metastatic disease, first-line

Renal cell carcinoma · 6 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 6 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Regorafenib monotherapy Variant #01	—	R 132 655	28d	~3.6 mo	~9.4 mo	~2	~R 265 310 PFS proxy · indirect	15
Lenvatinib and Pembrolizumab Variant #01	—	R 128 546	21d	~23.9 mo	—	~36	~R 4 545 663 PFS proxy · indirect	3
Everolimus and Lenvatinib Variant #01	—	R 48 788	21d	~14.7 mo	—	~2	~R 97 575 PFS proxy · indirect	4
Erlotinib and Bevacizumab Variant #01	—	R 26 036	28d	~9.9 mo	—	~52	~R 1 353 852 PFS proxy · indirect	1
Bevacizumab monotherapy Variant #01	—	R 19 082	14d	~8.5 mo	—	~2	~R 38 164 PFS proxy · indirect	1
Bevacizumab and Interferon alfa-2a Variant #01 Partial	—	R 19 082	14d	~9.8 mo	~20.8 mo	~27	~R 515 218 PFS proxy · indirect	4

6 of 6 regimens shown